Accumulation of IL-6 in the tumor microenvironment is associated with a functional defect in the DCs of cancer patients [12].This inhibitory effect is believed to be controlled by the IL-6-triggered activation of JAK2/STAT3 signaling in the DCs [13]. Here, IL6 is linked to neoplasm.